BCMA Targeted CAR T-cells

BIOLOGICAL3 trials

Sponsors

Zhejiang University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions

Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma

Early Phase 1

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Not yet recruitingNCT04670055

Zhejiang UniversityRefractory Multiple Myeloma, Relapse Multiple Myeloma

Start: 2021-01-01End: 2027-01-01Target: 50Updated: 2020-12-17

A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Zhejiang UniversityRefractory Multiple Myeloma, Relapse Multiple Myeloma

Start: 2022-06-20End: 2025-06-20Target: 100Updated: 2022-06-24

Study of SYS6020 in BCMA-positive Multiple Myeloma

Not yet recruitingNCT06359509

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyMultiple Myeloma

Start: 2024-04-30End: 2032-05-31Target: 10Updated: 2024-04-11

Related Papers

Predictive value of pre-treatment circulating tumor DNA genomic landscape in patients with relapsed/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy: Insights from tumor cells and T cells

Chinese Medical Journal2024-11-062 citations

Clinical Characteristics and Outcomes of BCMA-Targeted CAR-T Cell Recipients with Coronavirus Disease 2019 during the Omicron Wave: A Retrospective Study

Blood2024-11-05